Real-world genetic testing patterns in metastatic castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Real-world genetic testing patterns in metastatic castration-resistant prostate cancer

Published:2021-08 Issue:22 Volume:17 Page:2907-2921
ISSN:1479-6694
Container-title:Future Oncology
language:en
Short-container-title:Future Oncology

Author:

Shore Neal¹^ORCID,Ionescu-Ittu Raluca²^ORCID,Yang Lingfeng³,Laliberté François²^ORCID,Mahendran Malena²^ORCID,Lejeune Dominique²^ORCID,Yu Louise⁴^ORCID,Burgents Joseph³,Duh Mei Sheng⁴^ORCID,Ghate Sameer R³

Affiliation:

1. Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA

2. Analysis Group, Inc., Montreal, QC, H3B 0G7, Canada

3. Merck & Co., Inc., Kenilworth, NJ 07033, USA

4. Analysis Group, Inc., Boston, MA 02199, USA

Abstract

Aim: To assess the patterns of genetic testing for homologous recombination repair mutations in patients with metastatic castration-resistant prostate cancer (mCRPC) pre-PARP inhibitors approval. Patients & methods: mCRPC patients were selected in an oncology electronic medical records database. Patterns and predictors of testing for ATM, BRCA1/2, CDK12, PALB2 and FANCA gene alterations were assessed. Results: Of 5213 mCRPC patients, 674 (13%) had a documented genetic test. The number of tested patients increased from 1 in 2013 to 313 in 2018 (out of 3161 and 3010 clinically active patients, respectively). Receiving care in an academic oncology center (versus a community-based center) strongly predicted genetic testing (hazard ratio = 2.41). Conclusion: The use of and access to genetic testing pre-PARP inhibitor approval was suboptimal.

Funder

Merck Sharp & Dohme Corp.

Publisher

Future Medicine Ltd

Subject

Cancer Research,Oncology,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/fon-2021-0153

Reference28 articles.

1. Cancer facts & figures. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2020.html (2020).

2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed [February 10, 2021]. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

3. AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer

4. Integrative Clinical Genomics of Advanced Prostate Cancer

5. Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC).

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race;ClinicoEconomics and Outcomes Research;2024-09

2. Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer;JAMA Oncology;2024-07-01

3. Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches;JCO Precision Oncology;2024-05

4. Real-world prevalence of homologous recombination repair mutations in advanced prostate cancer: an analysis of two clinico-genomic databases;Prostate Cancer and Prostatic Diseases;2023-12-06

5. Pathogenic <i>BRCA2</i> c.6341del gene variant in a patient with prostatic cancer from the North Ossetia;Cancer Urology;2023-11-16